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oRIGINAL ARTICLE
Introduction: The staging of node-negative non–small-cell lung can-
cer is modified in the 7th edition TNM classification. Here, we pool 
data from the National Cancer Institute of Canada Clinical Trials 
Group JBR.10 trial and the Cancer and Leukemia Group B-9633 
trial to explore the prognostic and predictive effects of the new T-size 
descriptors and KRAS mutation status.
Methods: Node-negative patients were reclassified as T2a 
(>3–≤5 cm), T2b (>5–≤7 cm), T3 (>7 cm) or T ≤ 3 cm (≤3 cm, but 
other T2 characteristics).
Results: of 538 eligible patients, 288 (53.5%) were T2a, 111 (21%) T2b, 
62 (11.5%) T3, whereas 77 (14%) T≤3 cm were excluded to avoid con-
founding. KRAS mutations were detected in 104 of 390 patients (27%). 
T-size was prognostic for disease-free survival (p = 0.03), but borderline 
for overall survival (oS; p = 0.10), on multivariable analysis. Significant 
interaction between the prognostic value of KRAS and tumor size was 
observed for oS (p  = 0.01), but not disease-free survival (p = 0.10). There 
was a nonsignificant trend (p = 0.24) for increased chemotherapy effect on 
oS with advancing T-size (hazard ratio [HR] T2a 0.90, [0.63–1.30]; T2b 
0.69, [0.38–1.24]; and T3 0.57, [0.28–1.17]). The HR for chemotherapy 
effect on oS in T2a patients with KRAS wild-type tumors was 0.81 (p = 
0.36), whereas a trend for detrimental effect was observed in those with 
mutant tumors (HR 2.11; p = 0.09; interaction p = 0.05). Similar trends 
were observed in T2b to T3 patients with wild-type (HR 0.86; p = 0.62), 
and KRAS mutant tumors (HR 1.16; p = 0.74; interaction p = 0.58).
Conclusion: Chemotherapy effect seems to increase with tumor size. 
However, this small study could not identify subgroups of patients 
who did or did not derive significant benefit from adjuvant chemo-
therapy based on T-size or KRAS status.
Key Words: Non–small-cell lung cancer, KRAS mutations, 
Adjuvant chemotherapy, TNM staging, Tumor size.
(J Thorac Oncol. 2012;7: 963–972)
Recently, several randomized clinical trials and two individual patient data meta-analyses have confirmed a survival benefit 
for adjuvant cisplatin-based chemotherapy in stage II to IIIA 
non–small-cell lung cancer (NSCLC), with absolute improve-
ments in 5-year survival of 4% to 15%.1–5 Unplanned retrospec-
tive subset analyses of some trials also suggest potential benefit 
in node-negative patients with tumors that were 4 cm or more.6,7 
Importantly, all adjuvant chemotherapy trials reported to date are 
based on an outdated staging system, and preceded adoption of 
the Union Internationale Contre le Cancer/American Joint Cancer 
Committee (UICC/AJCC), 7th Edition Staging Classification of 
Lung Cancer.8–10 The implications of these changes on recommen-
dations for adjuvant chemotherapy use remain to be determined.
Clinical trials suggesting a potential benefit for adjuvant 
chemotherapy in node-negative NSCLC patients with tumors 
of 4 cm or more include the JBR.10 and Cancer and Leukemia 
Group B (CALGB)-9633 trials.6,7 However, the 4-cm tumor 
cutpoint was reached arbitrarily. Furthermore, as this size 
does not correspond to the T-size descriptors used in either 
the old or new TNM staging systems, practical questions are 
raised regarding its clinical application and how best to utilize 
this finding in future studies.
The UICC/ AJCC 7th edition particularly alters the stage 
classification of stage-I tumors.8,9 T1 tumors now are subclas-
sified as T1a (≤2 cm) and T1b (>2–≤3 cm), T2 tumors as T2a 
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(>3–≤5 cm), and T2b (>5–≤7 cm), with tumors more than 7 
cm reclassified as T3. This results in upstaging of pT2bN0 
from IB to IIA, and pT3N0 to IIB. Whether the new staging 
system better stratifies patients for benefit from adjuvant che-
motherapy remains to be determined.
The selection of NSCLC patients for adjuvant chemo-
therapy on the basis of stage alone, however, is suboptimal, 
with high rates of relapse observed. This has led to attempts 
to identify other potential predictive markers of chemotherapy 
benefit. Analyses of both JBR.10 and CALGB-9633 suggested 
that the presence of KRAS mutations may be associated with 
resistance to platinum-based chemotherapy, although neither 
study could demonstrate a significant interaction.11,12 We ques-
tioned, therefore, whether the interaction of tumor size and 
KRAS status might predict for adjuvant chemotherapy benefit 
in node-negative NSCLC patients.
In this retrospective study, we pooled data from JBR.10 
and CALGB-9633 to provide the first exploratory analysis 
of the effect of the new T-size descriptors on survival benefit 
from adjuvant platinum-based chemotherapy in node-negative 
NSCLC patients. Furthermore, we explored the interaction 
between T-size and KRAS mutation status in predicting benefit 
from adjuvant chemotherapy. Finally, we evaluated the interac-
tion between the prognostic values of T-size and KRAS mutation 
status on overall survival (oS) and disease-free survival (DFS).
PATIENTS AND METHODS
Study Population
All node-negative (N0) patients randomized to receive 
either adjuvant chemotherapy or observation as part of JBR.10 
and CALGB-9633 were eligible. Methodology of both clinical 
trials has been described previously.4,7 Pathological confirma-
tion of negative lymph nodes at mediastinoscopy and/or sur-
gery was mandatory for inclusion in the CALGB-9633 study; 
whereas for JBR.10, intraoperative mediastinal lymph-node 
resection or biopsy of nodes of 1.5 cm or more was required. 
CALGB-9633 was limited to patients with pT2N0 NSCLC, 
whereas JBR.10 included patients with completely resected 
pT2N0, pT1N1, or pT2N1 NSCLC. In CALGB-9633, car-
boplatin/paclitaxel was administered for four postoperative 
cycles, and in JBR.10, cisplatin/vinorelbine was administered, 
also for four cycles.
KRAS Gene Mutation Assay
Pretreatment tumor specimens were collected pro-
spectively in both trials. Available specimens were evaluated 
for the presence of KRAS mutation (codons 12, 13, and 61) 
using allele-specific oligonucleotide hybridization followed 
by confirmation by sequencing in JBR.10 and mass-spec-
trometry–based genotyping in CALGB-9633, as previously 
described.11,12
Statistical Analysis
Individual patient data including tumor size and survival 
status were collected for all eligible patients. Node-negative 
patients were reclassified by tumor size as T2a (>3–≤5 cm), 
T2b (>5–≤7 cm), T3 (>7 cm), or the T ≤ 3 cm subgroup (tumor 
size ≤ 3 cm but with other T2 defining characteristics: involve-
ment of the bronchus ≥2 cm distal to the carina; the presence 
of visceral pleural invasion; atelectasis or pneumonitis extend-
ing to the hilar region but not involving the entire lung). The 
T ≤ 3 cm subgroup represented a potential source of con-
founding because it included patients upstaged to T2 by virtue 
of factors other than tumor size. Because it was not possible to 
study the influence of these factors on outcome as a result of 
insufficient cases and incomplete data, the T ≤ 3 cm subgroup 
was excluded from analyses to avoid bias. The primary end 
point of the study was oS. The secondary end point was DFS, 
defined as time to recurrence, or death from any cause in the 
absence of recurrence.
Median follow-up was calculated using the reverse 
Kaplan-Meier method.13 Analyses comparing the chemo-
therapy and control arms used an intention-to-treat principle. 
Survival analyses were performed using the log-rank test 
method and the Cox model stratified by trial and adjusted 
for age, sex, histology, and type of surgery. The hazard ratios 
(HRs) corresponding to univariable analyses are displayed in 
all survival curves shown, whereas the results of multivariable 
analyses are reported in the Results section. The main analysis 
was the multivariable analysis.
The treatment effect variation by T-size for survival was 
studied using tests for trend. The T2b and T3 subgroups were 
pooled for analyses evaluating the effect of KRAS mutations 
because of the limited number of events observed. We planned 
to evaluate the prognostic value of T-size and its interaction 
with KRAS mutation status in the control group of the relevant 
study cohort, except in the absence of interaction of these vari-
ables with treatment effect, in which case, an analysis using 
both chemotherapy and control arms, stratified by treatment 
arm, would be performed.
Statistical analyses were performed using SAS Software, 
version 9.1 (SAS Institute, Cary, NC). Survival curves were 
performed using R software, version 2.13.0 (copyright 2011 




JBR.10 included 482 patients with completely resected 
stage-IB (T2N0, n = 219) or -II (T1-2N1, n = 263) NSCLC. 
CALGB-9633 included 344 stage-IB (T2N0) NSCLC patients. 
After pathological review, 218 of 219 JBR.10 and 331 of 
344 CALGB-9633 N0 patients remained eligible for study. 
Tumor-size data were available for 538 of 549 N0 patients 
(Fig. 1). Among these, 288 were T2a, 111 T2b, and 62 T3 
by T-size criteria based on the new 7th edition TNM Staging 
Classification.
Baseline characteristics of the study population, by 
tumor size, are presented in Table 1. CALGB-9633 included a 
higher proportion of patients with larger tumors (p < 0.0001). 
Adenocarcinomas tended to be smaller relative to other histo-
logical subtypes (p = 0.03). Large tumors more often required 
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pneumonectomy (p < 0.0001). There were no significant 
differences among the subgroups with respect to the treat-
ment received (p = 0.10). Median follow-up was 5.3 years 
for JBR.10 and 7.5 years for CALGB-9633 (6.5 years for all 
study participants).
KRAS Mutations
KRAS mutation testing was successful for 390 of 461 
patients (85%) (174 of 185  JBR.10 [94%] and 216 of 276 
CALGB-9633 [78%]). In total, 104 of 390 patients  (27%) had 
tumors with KRAS mutation (Table 2). There was no signifi-
cant association between the distribution of KRAS mutations 
and tumor size according to the new T-size descriptor catego-
ries (p = 0.49).
Prognostic Effect of Tumor Size for OS and DFS
The prognostic value of tumor size for oS and DFS was 
analyzed in the control group of the T-size population because 
of a trend for interaction between tumor size and treatment 
effect on DFS (p = 0.10). In multivariable analysis, tumor 
size was significantly prognostic for DFS (test for trend, p = 
0.03), but only borderline for oS (p = 0.10; Fig. 2A and 2B). 
Compared with T2a patients, the HR for recurrence was 1.09 
(95% CI, 0.70–1.71) for T2b and 2.07 (95% CI, 1.20–3.59) 
for T3, whereas the HR for death was 1.19 (95% CI, 0.75–
1.89) and 1.64 (95% CI, 0.91–2.97), respectively (reported 
in Supplementary Table 1, Supplemental Digital Content 1 
http://links.lww.com/JTo/A268).FIGURE 1. Study population.
TABLE 1. Baseline Demographics of Patients by T-size According to Seventh Edition Staging Classification
T2a (>3–≤5 cm) 
n = 288




T≤3cm (≤3 cma) 
n = 77
p ValueNo. No. No. No.
Clinical trial
 JBR.10 128 38 19 33 <0.0001
 CALGB 9633 160 73 43 44
Treatment
 JBR.10
  Chemotherapy 72 21 9 8 0.10
  observation 56 17 10 25
 CALGB-9633
  Chemotherapy 80 34 25 21
  observation 80 39 18 23
Age at diagnosis (yrs)
 Median 61 61 59 60 0.73
 Range 34–81 37–76 42–78 40–78
Age groups (yrs)
 <55 83 33 18 18 0.91
 55–64 98 39 20 32
 >64 107 39 24 27
Sex
 Male 184 71 41 45 0.79
 Female 104 40 21 32
(Continued)
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Prognostic Effect of Tumor Size by KRAS 
Mutation Status for OS and DFS
The prognostic effect of tumor size on oS by KRAS 
mutation status is shown in Figure 3. Among patients with 
KRAS mutant tumors, those with tumors bigger than 5 cm had 
a significantly worse survival (HR = 2.38, 95% CI, 1.30–4.35, 
p = 0.005) (Fig. 3B). In contrast, there was no significant 
difference in the risk of death according to tumor size among 
patients with KRAS wild-type tumors (HR 0.96, 95% CI, 0.66–
1.40; p = 0.82) (Fig. 3A). Significant interaction between the 
prognostic values of T-size and KRAS mutation was observed 
for oS (interaction p = 0.01), but not DFS (interaction 
p = 0.10).
Predictive Value of Tumor Size for Survival 
Benefit from Adjuvant Chemotherapy
Pooled analysis of the 461 patients in the T-size popula-
tion revealed an overall significant beneficial effect of adju-
vant chemotherapy for DFS (HR 0.75, 95% CI, 0.57–0.98, 
p = 0.04), and a slightly smaller effect for oS (HR 0.80, 95% 
CI, 0.60–1.06, p = 0.13). In multivariable analysis, a nonsig-
nificant trend toward increased DFS benefit from adjuvant 













JBR 10 Wild-type 87 35 25 27 14 27 126 32
Mutated 35 14 9 10 4 8 48 12
CALGB-
9633
Wild-type 94 38 46 51 20 38 160 41
Mutated 31 13 11 12 14 27 56 15
All KRAS
Wild-type 181 73 71 78 34 65 286 73
Mutated 66 27 20 22 18 35 104 27
All 247 100 91 100 52 100 390 100








T≤3cm (≤3cma)  
n = 77
p ValueNo. No. No. No.
ECoG performance status
 0 167 59 27 41 0.21b
 1–2 120 51 35 35
 Unknown 1 1 0 1
Type of surgery
 Pneumonectomy 26 15 19 3 <0.0001b
 Lobectomy 259 96 43 74
 Unknown 3 0 0 0
Histological subtype
 Adenocarcinoma 145 50 28 52 0.03b
 Squamous 99 37 24 13
 other 43 24 10 12
 Unknown 1 0 0 0
aT≤3cm but with other T2 defining characteristics (excluded from analyses). 
bExcluding unknown category.
CALGB, Cancer and Leukemia Group B; ECoG, Eastern Cooperative oncology Group.
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chemotherapy was observed with increasing tumor size: HR 
0.85 (95% CI, 0.61–1.20) for T2a, 0.73 (95% CI, 0.42–1.28) 
for T2b and 0.41 (95% CI, 0.21–0.82) for T3 (test for trend 
p = 0.10) (Fig. 4A–4C ). Similarly, we observed a nonsignifi-
cant increase in effect of adjuvant chemotherapy on oS with 
advancing tumor size: HR 0.90 (95% CI, 0.63–1.30) for T2a, 
0.69 (95% CI, 0.38–1.24) for T2b, and 0.57 (95% CI, 0.28–
1.17) for T3 (test for trend p = 0.24) (Fig. 4D–4F).
Predictive Value of KRAS Mutation Status for 
Survival Benefit From Adjuvant Chemotherapy 
by Tumor Size
The predictive value of KRAS status for survival benefit 
from adjuvant chemotherapy by tumor size among the 390 evalu-
able patients is summarized in Figure 5. Among T2a patients, the 
HR for chemotherapy effect on oS was 0.81 (95% CI, 0.51–1.28; 
p = 0.36) in those with KRAS wild-type tumors, whereas a trend 
for detrimental effect was observed in those with KRAS mutations 
(oS HR = 2.11, 95% CI, 0.89–5.00; p = 0.09); this interaction was 
of borderline significance (p = 0.05). Among T2b to T3 patients, 
trends were in the same direction in those with KRAS wild-type 
tumors (oS HR = 0.86, 95% CI, 0.47–1.56, p = 0.62), and in 
those with KRAS mutations (oS HR = 1.16, 95% CI, 0.49–2.78, 
p = 0.74); however, this interaction was not significant (interac-
tion p = 0.58). Similar results were obtained for DFS (reported 
in Supplemental Table 2, Supplemental Digital Content 2, 
http://links.lww.com/JTo/A269), and Supplemental Figure 1, 
Supplemental Digital Content 3, http://links.lww.com/JTo/
A270).Finally, a three-way interaction between T-size, KRAS 
mutation status, and chemotherapy was not significant for either 
oS (p = 0.37) or DFS (p = 0.83).
DISCUSSION
Clinical trials supporting the use of adjuvant platinum-
based chemotherapy in completely resected NSCLC are based 
on a now outdated staging classification. The UICC/AJCC 7th 
edition Staging Classification of Lung Cancer dramatically 
alters the staging of node-negative NSCLC patients, and was 
incorporated into clinical practice without knowledge of the 
potential impact of these changes on recommendations for 
adjuvant chemotherapy in the new subgroups. The current 
Cancer Care ontario and the American Society of Clinical 
oncology guidelines for adjuvant chemotherapy in NSCLC 
are based on the 6th edition, and recommend use of adjuvant 
platinum-based chemotherapy in good performance patients 
with completely resected stage II to IIIA NSCLC, while citing 
insufficient evidence to endorse its routine use in stage IB.14 
However, given that the new staging system results in upstag-
ing of node-negative NSCLC patients with tumors more than 
5 cm from IB to IIA (>5–≤7 cm) and IIB (>7 cm), there is 
resultant uncertainty as to how these subsets of patients should 
be treated. This has prompted calls for further information 
regarding the impact of the new T-size descriptors on chemo-
therapy effect.15 To our knowledge, this retrospective study is 
the first to address this question by using pooled data from 
two pivotal adjuvant chemotherapy studies. Furthermore, we 
examine the potential of KRAS mutations as markers of resis-
tance to adjuvant platinum-based therapy to evaluate whether 
the interaction of T-size and KRAS mutation status might 
better predict for treatment effect.
In this study, reclassification of patients using the 7th 
edition T-size descriptors led to upstaging of one third of the 
node-negative population; 111 pT2b N0 patients from IB 
to IIA, and 62 pT3N0 patients from IB to IIB. This finding 
highlights the importance of the new T-size descriptors 
in influencing stage shifts, and is consistent with those of 
Boffa et al.16 who recently reported that 5.5% of all participants 
FIGURE 2. Disease-free (A) and overall survival (B) by tumor 
size in the control arm of the T-size population.
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in the International Association for the Study of Lung Cancer 
(IASLC) staging database were upstaged from IB on the basis 
of tumor size alone. Thus, our study reinforces the pressing 
need for improved understanding of the impact of the new 
T-size descriptors on adjuvant chemotherapy effect. This is 
particularly valid when we consider that up to 77% of sur-
veyed lung cancer physicians would alter patient management 
in response to a change in stage designation.16
In this retrospective study, we have shown an increasing 
effect of adjuvant chemotherapy with advancing tumor size; 
however, the interaction was not significant for oS, and was 
only borderline for DFS. Although not statistically significant, 
our findings are consistent with the pooled analysis, performed 
by Douillard et al., which showed an increase in treatment 
effect with tumor stage in patients randomized to cisplatin/
vinorelbine versus observation as part of the lung adjuvant 
cisplatin evaluation (LACE)-vinorelbine meta-analyses which 
were based on the 6th edition staging system.17 Unfortunately, 
the other participating studies in the LACE meta-analyses 
were not eligible for inclusion in our study as they lacked suf-
ficient T-descriptor data, including tumor size. The power of 
this study is, therefore, limited; this likely impacted on the 
ability to detect a significant difference or interaction from 
adjuvant chemotherapy based on the new T-size descriptors. 
Nonetheless, a clear trend for increased chemotherapy effect 
in the T2b and T3 subgroups was observed, with a suggestion 
of clinically meaningful benefit from adjuvant chemotherapy 
in this population. Indeed, the HRs for mortality of 0.69 for 
pT2bN0 and 0.57 for pT3N0 patients, although not statistically 
significant, are not dissimilar to those observed for stage-II 
patients (HR = 0.83 [0.73–0.95]) in the LACE meta-analy-
sis.5 Caution must be exercised in interpreting these results, 
however, as there was no statistically significant interaction 
between treatment and tumor size in our relatively small study. 
Confirmatory data of the benefit of adjuvant chemotherapy in 
node-negative NSCLC from large-scale prospective trials are, 
therefore, warranted.
In this exploratory analysis, patients with completely 
resected pT2aN0 NSCLC did not seem to derive significant 
benefit from adjuvant platinum-based chemotherapy. This is 
not surprising, given that this subgroup includes node-neg-
ative patients with tumors 3 to 5 cm in size, and individual 
retrospective analyses of the CALGB-9633 and JBR.10 tri-
als have suggested previously that node-negative patients with 
tumors less than 4 cm do not benefit from adjuvant chemo-
therapy. Nonetheless, the question still remains as to how to 
treat patients with tumors that are 4 to 5 cm in size as this 
study lacked sufficient power to examine this extremely small 
subgroup.
Previous analyses of JBR.10 and CALGB-9633 
suggested that the presence of KRAS mutations may be 
associated with resistance to platinum-based adjuvant 
chemotherapy.11,12 We undertook exploratory analyses, there-
fore, to determine whether there might be interaction of 
KRAS mutations and tumor size on treatment effect in this 
population. We identified KRAS mutations in the tumors of 
27% of evaluable patients, a rate higher than that observed 
in a meta-analysis of literature conducted by Mascaux et al.18 
Consistent with previously reported studies, there was a sug-
gestion, although not significant, that patients with KRAS 
wild-type tumors may benefit from adjuvant chemotherapy, 
whereas those with KRAS mutant tumors did not seem to ben-
efit from treatment. However, this relatively small study could 
not identify any particular subgroup of patients who did or 
did not derive significant benefit from adjuvant chemotherapy 
based on T-size and KRAS mutation, and so this cannot be 
recommended as a means of selecting patients for receipt of 
adjuvant chemotherapy.
FIGURE 3. Overall survival by tumor size among the 390 patients with both T-size and KRAS data available: (A) KRAS  
wild-type and (B) KRAS mutated tumors (HR for univariable analysis).HR, hazard ratio.
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FIGURE 4. Disease-free survival (A–C) and overall survival (D–F) (chemotherapy versus control) in the T2a, Tb2, and T3 
subgroups.
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FIGURE 5. Overall survival curves (chemotherapy versus control) for the T2a and T2b-T3 subgroups among patients with KRAS 
wild type tumors (A, B) and patients with KRAS mutant tumors (C, D).
Tumor size was significantly prognostic for DFS, and 
borderline for oS in this study. The power of our study was 
limited, however, with the results highly dependent on a small 
group of T3 patients. As such, we could only validate the 
7th edition T-size descriptors partially in this node-negative 
population. Indeed, the prognostic significance of the T-size 
descriptors, proposed by the IASLC staging committee, was 
based on analyses of more than 7000 NSCLC patients who 
underwent complete surgical resection without prior induc-
tion therapy.8 A recent single-center review of 1805 cases of 
resected NSCLC also confirmed the prognostic significance 
of the 2, 3, and 7-cm cutpoints in the seventh edition, although 
the 5-cm cutpoint could not be validated.19 Similarly, a sepa-
rate single-institution review of 1393 NSCLC patients inde-
pendently confirmed the prognostic significance of all the new 
T-size descriptors in the total study population, although the 
prognostic significance of the 5-cm cutpoint was lost when 
analyses were confined to the node-negative subgroup.20 
Interestingly, a recent study has suggested that microscopic 
vascular invasion is a stronger prognostic indicator than T-size 
in the T1a-T2b subgroups.21
A significant interaction between the prognostic value 
of KRAS mutations and tumor size was observed for oS, 
but not DFS in this study. This was an unexpected finding 
given the larger number of events included in the DFS analy-
ses. However, the presence of KRAS mutations significantly 
increased the risk of death only in patients with T2b and T3 
tumors. Previous studies evaluating the prognostic value of 
KRAS mutations in NSCLC have shown mixed results. The 
meta-analysis, conducted by Mascaux et al.18 identified the 
presence of RAS mutations as a negative prognostic factor 
in NSCLC (HR = 1.40, 95% CI, 1.18–1.65). However, there 
was no significant prognostic effect for RAS mutation sta-
tus in a previous retrospective analysis of stage Ib-II (by the 
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6th edition) NSCLC patients in JBR.10 11, or for KRAS muta-
tion status in a pooled analysis of 1751 NSCLC patients 
included in the LACE-bio analysis.22 Furthermore, in a ran-
domized trial comparing postoperative radiation therapy to 
radiation therapy and chemotherapy in stage II-to-IIA NSCLC, 
the presence of KRAS mutations was not independently prog-
nostic on multivariable analysis.23
The  T ≤ 3 cm subgroup represented a potential source 
of confounding in this study as it included patients who were 
classified as T2 by virtue of T2-defining characteristics other 
than tumor size. Meaningful conclusions can, therefore, be 
drawn only from the analyses that excluded this subgroup. 
These T2-defining descriptors include: involvement of the 
bronchus 2 cm or more distal to the carina, the presence 
of visceral pleural invasion, and atelectasis or pneumoni-
tis extending to the hilar region but not involving the entire 
lung. Several studies have suggested that the presence of 
one or more of these T-descriptors confers poor prognosis in 
NSCLC,24–28 although the recent IASLC staging project was 
unable to address this issue because of insufficient clinical 
data.8 Nonetheless, if it is accepted that these T-descriptors are 
prognostic for poor outcome, one can postulate that they may 
potentially also predict independently for adjuvant chemo-
therapy effect. Unfortunately, data regarding the coexistence 
of T-descriptors other than size were incomplete for the T2a 
to T3 subgroups, thereby precluding analysis of their effect in 
multivariable analyses.
Prospective data from large adjuvant chemotherapy 
trials are necessary before clinical guidelines regarding 
management of surgically resected node-negative NSCLC 
can be updated to reflect the changes introduced by the 7th 
edition staging system. The results of ongoing studies that 
prospectively are recording all T-descriptor data hopefully 
will provide valuable information in this regard. However, 
until these results become available, this retrospective explor-
atory analysis supports treatment of pT2bN0 and pT3N0 
NSCLC patients with adjuvant platinum-based chemotherapy 
as per existing guidelines for stage-II patients. on the basis 
of previous reports, chemotherapy should not be recom-
mended in node-negative patients with tumor size less than 
4 cm; however, optimal treatment of patients with tumor 
size 4 to 5 cm remains unclear. Despite the trends observed 
in this relatively small study, at this time, KRAS mutational 
status cannot be recommended as a means of identifying 
node-negative NSCLC patients who may or may not 
benefit from adjuvant chemotherapy. Finally, it should be remem-
bered that evolving technologies such as gene prognostic signa-
tures have shown promise in predicting for adjuvant chemotherapy 
benefit, and may aid clinical decision making in the future.29
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